Erasca Inc是一家临床阶段精准肿瘤学公司。该公司专注于发现、开发和商业化针对RAS/MAPK通路驱动的癌症的疗法。该公司从事肿瘤学和RAS靶向治疗,以创建旨在全面关闭RAS/MAPK通路以治疗癌症的疗法和组合方案。该公司的主要候选产品是ERAS-007和ERAS-601,它们共同构成了其第一个MAPKlamp。ERAS-007被设计为ERK1/2的口服抑制剂,已在Asana完成的晚期实体瘤患者的I期临床试验中作为单一药物进行了评估。ERAS-601是一种口服SHP2抑制剂,目前正在进行人体I期临床试验FLAGSHP-1。该公司的SHP2抑制剂旨在阻断致癌信号转导并延缓治疗耐药性的发生,这有可能成为针对RAS/MAPK通路改变的癌症的联合治疗的支柱。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Jonathan E. Lim | Co-Founder, Chairman & CEO | 2019 | 54 |
| James A. Bristol | Lead Independent Director | 2023 | 79 |
| Alexander Whitman Casdin | Independent Director | 2018 | 58 |
| Valerie Harding-Start | Independent Director | 2019 | 66 |
| Julie Hambleton | Independent Director | 2021 | 68 |
| Pratik S. Multani | Independent Director | 2018 | 59 |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 2020 | 68 |
| Karen Cichowski | Scientific Advisory Board Member | - | - |
| George Daniel Demetri | Scientific Advisory Board Member | - | 69 |
| Kevan M. Shokat | Scientific Advisory Board Member | - | - |
| Pablo Rodriguez-Viciana | Scientific Advisory Board Member | - | - |
| Ryan B. Corcoran | Scientific Advisory Board Member | - | - |
| Stephen C. Blacklow | Scientific Advisory Board Member | - | - |
| Bruce D. Roth | Member of Research, Development, & Commercial Advisory Board | - | - |
| Jean I. Liu | Independent Director | 2022 | 58 |
| John Lo | Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board | 2022 | - |
| Rene Bernards | Member of Scientific Advisory Board | - | 73 |
| Piro Lito | Member of Scientific Advisory Board | 2025 | - |
| Jean-Michel Vernier | Senior Chemistry Advisor & Member of Research, Development and Commercial Advisory Board | 2025 | 64 |